Email Us: info@lupinepublishers.com
Call Us: +1 (914) 407-6109
57 West 57th Street, 3rd floor, New York - NY 10019, USA
Lupine Publishers Group
Lupine Publishers
ISSN: 2637-4579
Review Article(ISSN: 2637-4579) 
Diabetes, Dipeptidyl Peptidase IV and Wound Healing: from Basic Science to Therapeutic Possibilities
Volume 2 - Issue 5Lara Baticic Pucar1*, Alaa Sharbini2, Jadranka Varljen1, Ester Pernjak Pugel3, Antonijo Grcic2 and Dijana Detel1
-
Author Information
Open or Close
Lara Baticic Pucar, Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia
Received: August 30, 2018; Published: September 10, 2018
DOI: 10.32474/OAJBEB.2018.02.000147
Full Text
PDFAbstract
Diabetes mellitus, a chronic metabolic disease characterized by different pathological outcomes as a consequence of unsettled hyperglycemia, often accompanied with various complications such as chronic ulcers, represents a major socio-economic health problem. Dipeptidyl peptidase IV or CD26 molecule (DPP IV/CD26), is an omnipresent transmembrane protein with significant involvements in different physiological and pathological processes. It has been recognized as a therapeutic option in the treatment of hyperglycemia, especially in patients suffering from type 2 diabetes, given its capability to regulate the biological activity of incretins, which are major regulators of glucose homeostasis. Furthermore, DPP IV/CD26 has been indicated to be involved in the regulation of inflammatory processes as well as cell proliferation and angiogenesis. New scientific evidence shows that inhibition of DPP IV/CD26 leads to a more efficacious healing of chronic ulcers in diabetic patients as well as in mice models of wounded tissue restoration. However, the role of DPP IV/CD26 in the process of wound healing in hyperglycemia is not entirely known. Our aim was to summarize most important findings on the involvement of DPP IV/CD26 in the regulation of glycemia as well as tissue regeneration and reparation. This work reviews basic biochemical mechanisms and therapeutic possibilities of DPP IV/CD26 inhibition as a good candidate in the therapy of diabetic wound healing.
Keywords: CD26 molecule; Diabetes; Dipeptidyl-peptidase IV; Hyperglycemia; Chronic Metabolic Disease; Wound healing; Glucose Homeostasis
Editorial Manager:
Email:
biomedicalengineering@lupinepublishers.com
-
Mark E Smith
Bio chemistry
University of Texas Medical Branch, USA -
Lawrence A Presley
Department of Criminal Justice
Liberty University, USA -
Thomas W Miller
Department of Psychiatry
University of Kentucky, USA -
Gjumrakch Aliev
Department of Medicine
Gally International Biomedical Research & Consulting LLC, USA -
Christopher Bryant
Department of Urbanisation and Agricultural
Montreal university, USA -
Robert William Frare
Oral & Maxillofacial Pathology
New York University, USA -
Rudolph Modesto Navari
Gastroenterology and Hepatology
University of Alabama, UK -
Andrew Hague
Department of Medicine
Universities of Bradford, UK -
George Gregory Buttigieg
Maltese College of Obstetrics and Gynaecology, Europe -
Chen-Hsiung Yeh
Oncology
Circulogene Theranostics, England -
.png)
Emilio Bucio-Carrillo
Radiation Chemistry
National University of Mexico, USA -
.jpg)
Casey J Grenier
Analytical Chemistry
Wentworth Institute of Technology, USA -
Hany Atalah
Minimally Invasive Surgery
Mercer University school of Medicine, USA -
Abu-Hussein Muhamad
Pediatric Dentistry
University of Athens , Greece
